Skip to content

Diagnostic value and clinical application of laminin gamama 2 in hepatocellular carcinoma with microvascular invasion

Diagnostic value and clinical application of laminin gamama 2 in hepatocellular carcinoma with microvascular invasion

Status
Active, not recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061064
Enrollment
Unknown
Registered
2022-06-15
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer

Interventions

Gold Standard:pathology
Index test:Laminin gamma 2

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients who met the clinical criteria for HCC; 2. Patients who underwent primary surgery for HCC or were initially diagnosed with typical imaging features; 3. The hospitalization data is intact; 4. Not complicated with other serious diseases (including tumors of other sites)

Exclusion criteria

Exclusion criteria: 1. Patients or family members did not consent to participate in the trial; 2. Liver involvement was not the primary admission diagnosis; 3. Age was less than 18 years or more than 80 years; 4. Pregnancy was complicated; 5. Severe complications, including end-stage lung disease, unstable coronary heart disease or heart failure 3-4, chronic kidney disease 4-5; 6. Immune deficiency; 7. Incomplete data.

Design outcomes

Primary

MeasureTime frame
Cancer Detection Rate;

Countries

China

Contacts

Public ContactHu Minggen

Chinese PLA General Hospital

hmg301@126.com+86 13910385269

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026